News
The assay, developed by ValiRx subsidiary Inaphaea, uses patient-derived cells to predict sensitivity to drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback